Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases

Author(s): Decheng Yang, Alhousseynou Sall, Zhen Liu, Huifang M. Zhang, Ji Yuan, Travis Lim and Yue Su

Volume 5, Issue 1, 2008

Page: [49 - 58] Pages: 10

DOI: 10.2174/157016308783769478

Price: $65

Abstract

MicroRNAs (miRNAs) are endogenous, short, double-stranded and noncoding RNA molecules that have been identified in a variety of organisms and certain viruses. This group of new molecules is transcribed mainly from the introns and/or exons or intergenic regions and plays important regulatory roles in development and gene expression. Mature miRNAs are typically 20-24 nucleotides in length and regulate target mRNAs post transcriptionally by interactions with partially mismatched sequences in the 3 ’ untraslated regions of these messengers. These interactions result in the suppression of translation or degradation of target mRNAs. At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development. In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy. Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.

Keywords: miRNA, RNAi, siRNA, antisense oligonucleotides, therapeutics, gene regulation antiviral


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy